FOLD News and Press, Amicus Therapeutics Inc. From 03/08/22

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42 nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T. A ...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Amicus Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Amicus Therapeutics, Inc. (FOLD) Q4 2021 Earnings Conference Call February 24, 2022 8:30 AM ET Company Participants Andrew Faughnan – Executive Director-Investor Relations John Crowley – Chairman and Chief Executive Officer Bradley Campbell – President and Chief Operating...

Amicus Therapeutics press release (NASDAQ:FOLD): FY GAAP EPS of -$0.92 misses by $0.16. Revenue of $305.51M (+17.1% Y/Y) misses by $1.21M. Outlook: For the full-year 2022, the Company anticipates total Galafold revenue of at least $350 million to $365 million. Non-GAAP operating expense ...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with...

Galafold ® Revenue Growth of 17% YoY to $306M in 2021 Galafold Global Sales Growing at Double-Digits (15-20%) with $350M-$365M in 2022 U.S. and EU Regulatory Filings Under Review and Launch Preparations Accelerating for AT-GAA in ...

Amicus Therapeutics (NASDAQ:FOLD) is scheduled to announce FY earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.79 (+26.2% Y/Y) and the consensus Revenue Estimate is $306.72M (+17.6% Y/Y). Over the last 1 year, FOLD has beaten EPS estimates 25%...

PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2021. ...

PHILADELPHIA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that two oral presentations and 11 posters across its develop...